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The BTNL2 gene is a member of the B7 receptor family that probably functions as a T-cell costimulatory molecule.
It resides in the class II major histocompatibility complex (MHC) region of chromosome 6p and has recently been
associated with sarcoidosis susceptibility in a white German population. We sought to replicate the BTNL2 as-
sociation in an African American family-based study population ( nuclear families) and two case-controlnp 219
populations—one African American ( pairs) and one white ( pairs). Ten SNPs were detected withinnp 295 np 366
a 490-bp region spanning exon/intron 5 of BTNL2. Haplotype variation within this region was significantly associated
with sarcoidosis in all three study populations but more so in whites ( ) than in the African AmericanPp .0006
case-control ( ) or family-based ( ) samples. The previously reported BTNL2 SNP with the strongestPp .02 Pp .03
sarcoidosis association, rs2076530, was also the SNP with the strongest association in our white population (P !
). The A allele of rs2076530 results in a premature exon-splice site and increases risk for sarcoidosis (odds.0001
; 95% confidence interval 1.32–3.12). Although rs2076530 was not associated with sarcoidosis inratiop 2.03
either African American sample, a three-locus haplotype that included rs2076530 was associated with sarcoidosis
across all three study samples. Multivariable logistic regression analyses showed that BTNL2 effects are independent
of human leukocyte antigen class II genes in whites but may interact antagonistically in African Americans. Our
results underscore the complexity of genetic risk for sarcoidosis emanating from the MHC region.
Sarcoidosis, a multiorgan granulomatous inflammatory
disease, probably results from an exaggerated T-cell re-
sponse to an airborne antigen (American Thoracic So-
ciety et al. 1999). Whereas human leukocyte antigen
(HLA) genes have long been thought to play a role in
sarcoidosis (Martinetti et al. 2002), the high density of
immune-related genes and linkage disequilibrium (LD)
in the major histocompatibility complex (MHC) region
create difficulties in separating out individual gene effects
(Cullen et al. 2002; Walsh et al. 2003; Stenzel et al. 2004).
Following-up a previously detected HLA linkage to sar-
Received February 10, 2005; accepted for publication June 29, 2005;
electronically published July 20, 2005.
Address for correspondence and reprints: Dr. Michael C. Iannuzzi,
Division of Pulmonary, Critical Care, and Sleep Medicine, Mount Sinai
Medical Center, 1 Gustave Levy Place, Box 1232, New York, NY 10029.
E-mail: Michael.Iannuzzi@mssm.edu
* The members of the ACCESS (A Case-Control Etiologic Study of
Sarcoidosis) Research Group are listed in the Acknowledgments.
 2005 by The American Society of Human Genetics. All rights reserved.
0002-9297/2005/7703-0016$15.00
coidosis (Schurmann et al. 2001), Valentonyte et al.
(2005) reported a novel association with rs2076530, a
coding SNP on exon 5 of the BTNL2 gene (MIM
606000), that is independent of HLA-DRB1 sarcoidosis
risk alleles. The rs2076530 GrA transition leads to an
alternative splice site that results in an early stop codon
and a truncated protein. BTNL2, aliases “butyrophilin-
like 2” and “BTL-2,” is a butyrophilin gene that belongs
to the immunoglobulin gene superfamily and is related
to the B7.1 and B7.2 (CD80 and CD86) costimulatory
receptors (Rhodes et al. 2001; Sharpe and Freeman 2002),
but its exact function is unknown. Optimal T-cell acti-
vation requires antigen engagement of the T-cell recep-
tor with additional costimulatory interactions. CD28,
expressed in T cells, binds to either the B7.1 or B7.2
counterreceptors on antigen-presenting cells (Shahinian
et al. 1993; Krinzman et al. 1996). Dysfunctional BTNL2
could interfere with normal T-cell regulation (Harding
et al. 1992).
The close proximity of BTNL2 to HLA-DRB1 and
HLA-DQB1, which have known sarcoidosis risk alleles
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Table 1
Study Samples
POPULATION
CHARACTERISTICS
FINDINGS FOR
African
American
Family
Sample
African
American
Case-Control
Sample
White
Sample
Cases:
n 241 295 366
Percentage Male 27.0 26.4 42.6
Mean age  SD (years) 44.3 9.0 40.3 9.7 43.6 10.6
Controls:
n 254 295 366
Percentage Male 35.4 26.4 42.6
Mean age  SD (years) 46.3 10.7 40.3 10.1 43.7 10.5
(Sato et al. 2002; Iannuzzi et al. 2003; Rossman et al.
2003), complicates association studies. In populations
of African origin, increased haplotype diversity in the
MHC class II region may help in differentiating specific
gene effects (Just et al. 1997). To determine the consis-
tency of the BTNL2 gene as a sarcoidosis risk factor
across different populations, we characterized variation
in the exon/intron 5 region of BTNL2 in an African
American family sample that consisted of 219 nuclear
families (686 individuals) and in two case-control sam-
ples (295 African American matched pairs and 366 white
matched pairs). The study protocols were approved by
institutional review boards of all participating centers.
In the African American family sample, which was as-
certained primarily from the Henry Ford Health System,
diagnosis was confirmed by tissue biopsy in 86% of the
index cases and in all index cases with normal (stage 0)
chest X-rays. Those subjects without histologic confir-
mation had radiographic evidence of bilateral hilar ad-
enopathy, a compatible clinical presentation, and were
observed for 2 years to verify that no other medical
condition could explain the clinical course. Of the 623
eligible probands identified, 359 (58%) were enrolled
with one or more first-degree family members. Of those
359 probands, 234 had at least two parents or siblings
who donated a blood sample. An additional 10 African
American families with sarcoidosis were recruited from
outside of the Henry Ford Health System, for a total of
244 families. Both parents were genotyped when avail-
able. When one or both parents were unavailable for
genotyping, all available full siblings were genotyped.
After exclusion of families with Mendelian inconsisten-
cies and insufficient DNA samples for analysis, the final
sample used for data analysis comprised 219 nuclear
families with 686 individuals (191 parents and 495 sib-
lings), of whom 241 were affected siblings (cases) and
254 were unaffected siblings (controls) (table 1). De-
tailed descriptions of this study population have been
published elsewhere (Rybicki et al. 2003, 2004).
African Americans and whites with sarcoidosis and
matched controls who participated in a case-control etio-
logic study of sarcoidosis (ACCESS) were also genotyped
for BTNL2. Between November 1996 and June 1999,
736 cases and 706 matched controls entered the study
(ACCESS Research Group 1999). Cases met the follow-
ing inclusion criteria: (1) first tissue confirmation of non-
caseating granulomas on biopsy within 6 mo of enroll-
ment, (2) clinical signs or symptoms consistent with sar-
coidosis, and (3) aged 18 years. Excluded were indi-
viduals with fungal disease or active tuberculosis or who
were receiving antituberculosis therapy. Patients with a
history of beryllium exposure were excluded unless they
had a negative blood beryllium-lymphocyte proliferation
test. The clinical characteristics of the study patients were
described elsewhere (Baughman et al. 2001).
Controls were recruited by random digit dialing and
were matched to cases on the basis of age (within 5
years), sex, and self-reported ethnicity and geographic
region. Potential controls who reported a history of sar-
coidosis or medical conditions that made the determina-
tion of affection status uncertain—for example, granu-
lomatous hepatitis or idiopathic uveitis—were excluded.
Of the 706 enrolled case-control pairs, 686 self-reported
that they were of white or African American ethnicity.
The present study included the 661 pairs in that subset
that had sufficient DNA remaining for genotyping (table
1).
Custom primer oligonucleotides for PCR and DNA
sequencing were designed from the reference sequence
surrounding rs2076530, to amplify a 490-bp amplicon
from each of the genomic samples. The primers used for
amplification and sequencing were 5′-AATGCACAGA-
GCATGGAGGTGAG-3′ and 5′-GAAGATACTGGAA-
AAGATACAAG-3′. PCR amplification of genomic DNA
was performed by standard PCR protocols. Quality con-
trol of PCR products was performed by agarose-gel elec-
trophoresis to confirm amplimer size. PCR products were
purified using commercial columns and then were se-
quenced by DNA cycle sequencing by use of BigDye Ter-
minator v3.1 chemistry. Sequence delineation and base
calling were performed using automated fluorescent DNA
sequencers, Applied Biosystems model 3730xl. For each
primer-template combination, a set of two sequencing
reactions was performed to get the required fourfold
redundancy (2 upstream, and 2 downstream) across the
template. SNPs were called for mixed nucleotide posi-
tions in which the second peak is 50% of the height
of the first peak.
Ten biallelic SNPs were identified in exon/intron 5 of
the BTNL2 gene (table 2). SNPs were detected at nu-
cleotide position (np) 15841 (A/T exon; Asp/Val), np
15843 (C/T exon; Arg/Ter), np 15932 (A/G exon; syn-
onymous rs2076529), np 15994 (C/T exon; Ser/Leu), np
16043 (G/A; synonymous rs9268480), np 16047 (G/A
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Table 2
National Center for Biotechnology Information
Accession Numbers, Flanking Sequences, and
Frequencies of Exon/Intron 5 BTNL2 SNPs in African
Americans and Whites
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
exon; Ala/Thr), np 16071 (A/G exon; premature trunca-
tion of mRNA by 4 bp/Gly rs2076530), np 16113 (C/T;
intron), np 16165 (T/C; intron), and np 16171 (T/C; in-
tron) (dbSNP). Of the 10 identified SNPs, 7 were novel,
and 4 of the 7 were coding SNPs that predicted amino
acid substitutions at positions 283, 284, 334, and 352 of
the BTNL2 protein. For each SNP, the proportion of het-
erozygous and homozygous genotypes was consistent
with Hardy-Weinberg equilibrium in cases and controls
across all three populations. Although all 10 SNPs were
detected in both African Americans and whites, 4 of
the SNPs—A15841T (accession number ss38346932),
C15843T (accession number ss38346933), G16047A
(accession number ss38346937), and T16171C (accession
number ss38346941)—were rare (frequency !1%) in
whites. Of the remaining six SNPs, four (G16043A,
A16071G, C16113T [accession number ss38346939],
and T16165C [accession number ss38346940]) captured
195% of the haplotype variation within this region. Since
A16071G was in complete LD with A15932G, is known
to be a functional SNP, and was the SNP reported else-
where to be associated with sarcoidosis (Valentonyte et
al. 2005), we chose it over A15932G for building hap-
lotypes across the region.
To determine whether an allele at the locus of interest
was associated with sarcoidosis, we used a family-based
association test statistic, S, calculated using the family-
based association testing software FBAT (Laird et al.
2000). BTNL2 haplotype data were analyzed using the
haplotype (HBAT) module in the FBAT software (Hor-
vath et al. 2004). Similar to FBAT, HBAT provides a test
in a family-based study that is efficient and robust to
population admixture, phenotype distribution specifica-
tion, and ascertainment based on phenotypes. As with
FBAT, HBAT can also handle missing parental genotypes
and/or missing phase in both offspring and parents.
HBAT yields either haplotype-specific (univariate) tests
or multihaplotype (global) tests. To increase statistical
power across the two African American samples, we
pooled P values for the haplotype tests. The overall P
value was computed by summing the natural logs of each
P value, multiplying by 2, and evaluating the result
on a x2 distribution curve with 4 df (2 # the number
of tests).
Case-control data were analyzed using matched lo-
gistic regression methods with the PHREG procedure in
SAS (SAS Institute). Haplotype data were analyzed with
CHAPLIN (case-control haplotype inference) software,
which uses a retrospective likelihood method that sums
over all possible pairs of haplotypes that are consistent
with the genotype data (Epstein and Satten 2003). LD
between selected pairs of loci in the case-control samples
was estimated in two stages. First, since haplotypes were
not directly observable, maximum-likelihood haplotype
frequencies were computed using the ARLEQUIN genetic
analysis software (Excoffier and Slatkin 1995). These hap-
lotype frequencies were then used to calculate the nor-
malized measure for LD between loci, D′ (Lewontin 1964;
Hedrick 1987).
Four haplotype-tagging SNPs in exon/intron 5 of
BTNL2 form five haplotypes with variable frequencies
and associations with sarcoidosis in the three different
study populations (table 3). The most frequent haplo-
type, G-A-C-T (haplotype 1), conferred 1.5-fold in-
creased risk for sarcoidosis ( ) in whites. Hap-Pp .00004
lotype 1 was observed in 66% of white cases but only
55% of controls. In the white sample, the A allele at np
16071 had an odds ratio (OR) for heterozygotes (AG
vs. GG) of 1.70 (95% CI 1.08–2.67) and an OR for
homozygotes (AA vs. GG) of 2.63 (95% CI 1.64–4.24).
This result is similar to what was observed in the original
report of BTNL2 (Valentonyte et al. 2005) in a white
German population (OR for AG vs. GG of 1.60; OR
for AA vs. GG of 2.75). In our white sample, individuals
who had one or more copies of the A allele had a twofold
increased risk of sarcoidosis ( ; 95% CI 1.32–ORp 2.03
3.12); the population attributable risk for AG hetero-
zygotes and AA homozygotes was 27.5%. Haplotype 1
was not associated with sarcoidosis in either African
American sample. The next most frequent haplotype in
African Americans, G-G-T-T (haplotype 2), was not as-
sociated with sarcoidosis in either the family or case-
control sample. In whites, haplotype 2 was underrep-
resented in cases ( ; ). The secondORp 0.60 Pp .006
most frequent haplotype in the white population—hap-
lotype 3, A-G-C-T—was also underrepresented in whites
with sarcoidosis ( ; ). A similar effectORp 0.74 Pp .02
was observed in African American families (transmission
distortion ; ) but not in the African[TD]p 0.76 Pp .02
American case-control sample. Haplotype 4, A-G-C-C,
was underrepresented in cases across all three samples,
but only in the African American case-control sample
did this haplotype show a significant negative associa-
tion with sarcoidosis ( ; ). The leastORp 0.44 Pp .001
frequent of the five haplotypes, G-G-C-T (haplotype 5),
conferred a modest increased risk of sarcoidosis in the
African American family sample ( ; )TDp 1.53 Pp .04
but showed no association with sarcoidosis in the other
two samples. Since the first three bases of haplotypes 3
and 4 were the same—A-G-C—we examined the risk
associated with this haplotype across all three samples.
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Figure 1 Level of association between sarcoidosis and variation
in the exon/intron 5 region of BTNL2 on the basis of the three-SNP
haplotype window moving across the region. The three study samples
analyzed include 219 African American nuclear families (blackened
circles), 295 African American case-control pairs (unblackened circles),
and 366 white case-control pairs (unblackened squares).
Table 3
Association between BTNL2 Haplotypes and Sarcoidosis in African Americans and Whites
HAPLOTYPEa
FINDINGS FOR
African American
Family Sample
( cases;np 241
254 controls)
African American
Case-Control Sample
( pairs)np 295
White Sample
( pairs)np 366
Frequencyb TD P Frequencyb OR P Frequencyb OR P
G-A-C-T 72.4 1.04 .26 68.9 1.16 .23 60.3 1.56 .00004
G-G-T-T 10.7 1.01 .89 13.4 1.26 .17 9.2 .60 .006
A-G-C-T 8.1 .76 .02 8.9 .92 .68 23.2 .74 .02
A-G-C-C 6.4 .86 .37 6.6 .44 .001 5.9 .83 .39
G-G-C-T 2.3 1.53 .04 2.2 .85 .69 1.3 1.04 .93
a Nucleotide sequence at BTNL2 np 16043 (rs9268480), np 16071 (rs2076530), np 16113, and np
16165.
b Haplotype frequency in overall sample.
The A-G-C haplotype was found in cases significantly
less often than expected in all three samples: TDp
( ) in the African American family sample;0.80 Pp .01
( ) in the African American case-ORp 0.65 Pp .009
control sample; and ( ) in the whiteORp 0.73 Pp .007
sample.
The haplotype distribution across BTNL2 exon/intron
5 was significantly associated with sarcoidosis in all three
populations. This association in African Americans was
more modest, in the family sample andPp .03 Pp
in the case-control sample, compared with the white.02
sample ( ). Pooling the independent P valuesPp .0006
from the two African American samples resulted in an
overall haplotype association P value of .006. Other less
common variants in this region specific to African Am-
ericans were increased in subjects with sarcoidosis in
the African American families, most notably A15841T
( ; ), C15843T ( ;TDp 1.50 Pp .06 TDp 1.61 Pp
), C15994T (accession number ss38346935) (.03 TDp
; ), and T16171C ( ; ).1.66 Pp .01 TDp 1.70 Pp .01
These four variants were in strong LD and had an in-
creased transmission to affected offspring in nuclear fami-
lies ( ; ). Of these four variants, threeTDp 1.70 Pp .01
(A15841T, C15843T, and C15994T) coded for predicted
amino acid changes, and an additional fourth novel non-
synonymous variant specific to African Americans was
found at np 16047. To determine whether these potential
functional coding changes add anything to the haplo-
typic variation analysis depicted in table 3, we reana-
lyzed the haplotypes with these four nonsynonymous
SNPs. In the family sample, all transmissions of the four-
locus variant haplotype of the nonsynonymous SNPs
occurred in tandem with haplotype 5 and therefore did
not add any additional haplotype-variation information.
In the African American case-control sample, the four-
locus variant haplotype occurred separate from the other
five haplotypes listed in table 3 but was observed with
an equal frequency in cases and controls (four times in
each); therefore, inclusion of these additional variants in
the haplotype calculation had only a nominal effect on
the statistical test for case-control differences in BNTL2
haplotype variation. In separate testing of three-locus
haplotype windows moving across this region, the low-
est P value of association in the white population was
centered at A15932G, but highly statistically significant
associations were observed for haplotypes across most
of the exon/intron 5 region (fig. 1). In the two African
American samples, the lowest P values were observed at
the far end of the exon 5 boundary. When we extended
the haplotype window outside of this boundary, the level
of association increased in the African American case-
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Table 4
LD between HLA Class II Genes and Exon/Intron 5 BTNL2
Haplotype-Tagging SNPs in Cases and Matched Controls
BTNL2 VARIANT
AND HLA CLASS II
LOCUS
D′ FOR
African
Americans
( pairs)np 187
Whites
( pairs)np 260
G16043A (rs9268480):
HLA-DRB1 .800 .835
HLA-DRB3 .137 .073
HLA-DQB1 .698 .658
HLA-DPB1 .209 .310
A16071G (rs2076530):
HLA-DRB1 .794 .607
HLA-DRB3 .100 .175
HLA-DQB1 .634 .485
HLA-DPB1 .209 .211
C16113T:
HLA-DRB1 .860 .615
HLA-DRB3 .211 .333
HLA-DQB1 .713 .480
HLA-DPB1 .251 .234
T16165C:
HLA-DRB1 .947 .860
HLA-DRB3 .166 .146
HLA-DQB1 .893 .693
HLA-DPB1 .537 .349
control sample but decreased in the African American
family sample.
To determine which SNP or set of SNPs most influ-
enced the observed haplotype associations with sar-
coidosis, we performed a stepwise model-building pro-
cedure for each sample. In the African American family
sample, a model with the G16043A SNP (rs2076529)
represented the best-fitting parsimonious model (Pp
). In the African American case-control sample, a.04
similar result was observed, in that a model with only
one SNP, T16165C, represented the best-fitting par-
simonious model ( ). In the white sample, thePp .02
best-fitting model included two SNPs, G16043A and
C16113T ( ).Pp .00004
Because of the proximity of BTNL2 to HLA class II
genes, we next investigated the extent of LD for the four
BTNL2 haplotype-tagging SNPs and the HLA class II
genes DRB1, DQB1, and DPB1 (table 4). Of the four
BTNL2 SNPs, DRB1 had the highest D′ values and
DRB3 had the lowest. In general, LD between the HLA
class II loci and BTNL2 was stronger in African Ameri-
cans than in whites. An examination of allele-specific
LD between HLA-DRB1 and the four BTNL2 SNPs
showed that, although most allele pairs were in complete
LD ( ), many allele pairs had D′ values !1 (fig.′D p 1
2A and 2B). In both whites and African Americans, the
BTNL2 SNPs G16043A and A16071G had the most
allele pairs in less-than-complete LD, whereas T16165C
had the fewest. Because of the strong LD between many
of the HLA-DRB1 alleles and BTNL2 and the previ-
ously found associations between HLA-DQB1 and HLA-
DRB1 in these samples (Iannuzzi et al. 2003; Rossman
et al. 2003), we performed multivariable logistic regres-
sion to determine the potential for confounding and ef-
fect modification of BTNL2 allelic effects from HLA
class II risk alleles. In the two case-control samples for
which data for both BTNL2 and HLA class II were
available, we tested three different types of logistic re-
gression models: (1) models with a term for only the
BTNL2 variant to estimate the crude OR for this variant
in the analysis subsample, (2) models with terms for the
BTNL2 variant and HLA class II risk allele to estimate
effects of confounding, and (3) models with terms for
the BTNL2 variant, the HLA class II risk allele, and
a cross-product interaction term to estimate effect
modification.
The BTNL2 alleles tested were those found signifi-
cantly associated with sarcoidosis in the two case-control
samples. The tested HLA class II alleles represent the
alleles that had the strongest race-specific associations
with sarcoidosis that were reported elsewhere for these
samples (Rossman et al. 2003). For African Ameri-
cans, we examined HLA class II allele effects on the asso-
ciation between the variant alleles of BTNL2 exon 5
SNPs G16043A and T16165C (table 5). In general, the
four HLA class II alleles associated with sarcoidosis in
this sample did not confound the relationship between
G16043A or T16165C and sarcoidosis. There was some
suggestion of negative interaction with DRB1*1201 and
positive interaction with DPB1*1101, but these inter-
action ORs did not reach statistical significance. In an
analysis that combined all four HLA class II risk alleles
into one risk group, we observed a statistically significant
( ) negative interaction between the BTNL2 SNPPp .01
G16043A and the HLA class II risk alleles. A similar
albeit weaker negative interaction was observed between
the BTNL2 SNP G16043A and the HLA class II risk
alleles in African Americans.
In our sample of whites, we examined HLA class II
allele effects on associations between the variant allele
of three BTNL2 exon 5 SNPs: G16043A, A16071G, and
C16113T. For G16043A and A16071G, similar nomi-
nal confounding effects were observed for the four HLA
class II alleles associated with sarcoidosis. HLA-DRB1*
0401 and HLA-DRB1*1501 slightly attenuated the OR
of the BTNL2 risk allele, whereas DRB1*0402 slightly
increased the OR. A parameter for the combined HLA
class II risk alleles slightly attenuated the OR for risk
alleles of G16043A and A16071G. For C16113T, an
adjustment for the combined effect of HLA class II risk
alleles decreased the OR from 0.66 to 0.58. Several in-
teraction ORs for joint BTNL2-HLA class II allelic ef-
fects 12 or !0.5 were observed, but none approached
statistical significance.
Figure 2 A, Incomplete disequilibrium (as measured by ) between allele pairs of HLA-DRB1 and the four BTNL2 exon/intron 5′1D
haplotype-tagging SNPs (G16043A [rs9268480], A16071G [rs2076530], G16113T, and T16165C) in whites with sarcoidosis and matched
controls ( pairs). B, Incomplete disequilibrium (as measured by ) between allele pairs of HLA-DRB1 and the four BTNL2 exon/′np 260 1D
intron 5 haplotype-tagging SNPs (G16043A [rs9268480], A16071G [rs2076530], G16113T, and T16165C) in African Americans with sar-
coidosis and matched controls ( pairs).np 187
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Table 5
HLA Class II Confounding and Effect Modification
of Associations between Sarcoidosis and Variant Alleles
of BTNL2 Exon/Intron 5 SNPs in Case-Control Pairs
Race, SNP, and Class II Allele aOR (P) iOR (P)
African American ( pairs):np 187
G16043A (rs9268480):
No allele 1.62 (.03) …
DRB1*1101 1.63 (.03) .67 (.42)
DRB1*1201 1.58 (.04) .26 (.13)
DRB1*1503 1.74 (.01) .72 (.64)
DPB1*1101 1.49 (.08) 1.52 (.33)
All four class II risk alleles 1.61 (.03) .32 (.01)
T16165C:
No allele 2.10 (.04) …
DRB1*1101 2.10 (.04) 1.05 (.94)
DRB1*1201 2.14 (.04) .38 (.46)
DRB1*1503a 2.27 (.02)
DPB1*1101 1.92 (.07) 1.47 (.52)
All four class II risk alleles 2.06 (.05) .45 (.21)
White ( pairs):np 260
G16043A (rs9268480):
No allele 1.33 (.04) …
DRB1*0401 1.14 (.37) 1.07 (.90)
DRB1*0402 1.51 (.005) .39 (.44)
DRB1*1101 1.29 (.08) .50 (.20)
DRB1*1501 1.16 (.31) .61 (.21)
All four class II risk alleles 1.35 (.03) .85 (.57)
A16071G (rs2076530):
No allele 1.48 (.003) …
DRB1*0401 1.36 (.02) .80 (.65)
DRB1*0402 1.61 (.0005) .36 (.41)
DRB1*1101 1.42 (.008) .92 (.88)
DRB1*1501 1.29 (.06) .79 (.53)
All four class II risk alleles 1.40 (.01) 1.05 (.86)
C16113T:
No allele 1.51 (.05) …
DRB1*0401 1.72 (.01) .87 (.91)
DRB1*0402a 1.46 (.08)
DRB1*1101 1.45 (.08) 3.09 (.23)
DRB1*1501 1.44 (.10) 1.35 (.59)
All four class II risk alleles 1.28 (.26) 1.31 (.57)
NOTE.—aOR p adjusted OR for the variant allele; iOR p inter-
action OR.
a Parameter not estimable for iOR and related P value.
On the basis of our findings in two different African
American samples, it appears that significant allelic het-
erogeneity exists at the BTNL2 locus. Resulting func-
tional differences in BTNL2 may be attenuated in the
sarcoidosis phenotype because of the high redundancy of
costimulatory molecules in the human immune system.
Whereas greater allelic diversity may explain in part the
more modest BTNL2 association observed in African
Americans, an alternative explanation may be an an-
tagonistic effect of HLA class II risk alleles on BTNL2-
associated risk. The gene-gene interaction results re-
ported by Valentonyte et al. (2005), although not con-
clusive, suggest that HLA-DRB1 is a risk factor for sar-
coidosis only in the presence of the truncating BTNL2
allele. Our interaction analyses of HLA class II risk al-
leles and BTNL2 in African Americans suggest that the
risk-bearing alleles of these two loci negatively interact.
The greater age and selective pressure on immune-related
genes in populations of African descent (Lazarus et al.
2002; Cao et al. 2004) (i.e., the explanation for the
greater genetic diversity observed in African Americans)
could explain this putative canceling effect of HLA class
II and BTNL2, with regard to sarcoidosis risk in African
Americans.
The exact functional role of BTNL2 in the costimu-
latory system remains to be elucidated. In demonstrating
an association between BTNL2 in both white Americans
and African Americans, we confirmed the initial report
of the BTNL2 gene association with sarcoidosis in white
Germans (Valentonyte et al. 2005). We also demon-
strated that BTNL2 risk effects observed in the white
samples were independent of HLA-DRB1 associations
found elsewhere for these samples (Rossman et al. 2003),
but we found suggestive evidence for negative interac-
tions between BTNL2 and HLA class II in African Am-
ericans. Larger samples will be needed to better define
these effects and to estimate them with a higher degree
of statistical certainty (Garcia-Closas and Lubin 1999).
Future studies should focus on defining the immunologi-
cal role of BTNL2 in granuloma formation in relation
to HLA class II.
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